For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Galantamine - Multiple sclerosis
PAD Profile : Galantamine - Multiple sclerosis
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Fampridine
- Fingolimod
- Glatiramer acetate
- Interferon beta
- Naltrexone hydrochloride
- Teriflunomide
- Modafinil
- Cladribine
- Ocrelizumab
- Biotin
- Ponesimod
- Ozanimod
- Peginterferon beta-1a
- Memantine hydrochloride
- Donepezil hydrochloride
- Rivastigmine
- Diroximal fumarate
- Alemtuzumab
- Dimethyl fumarate
- Natalizumab
- Ofatumumab
- Siponimod
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.
If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.
The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend AChE inhibitors* or memantine for people with cognitive impairment caused by multiple sclerosis, in line with NICE guideline (NG97)
* AChE inhibitors - donepezil, galantamine amd rivastigmine